The Centre for Innovation in Regulatory Science – CIRS recently published R&D Briefing 54, which looks specifically at trends in the number of New Active Substance (NAS) approval numbers and approval times across the following agencies’ processes: European Centralised, US FDA and Japananese PMDA. Approvals are often a measure of the pharmaceutical industry’s output and […]
written on 20.05.2014
Insight into New Drug Approvals in ICH Countries 2004-2013
